IP Library › Granted Patent US 9,562,083

Granted Patent B2

US 9,562,083 · App. 14/609,128 · Granted Feb 7, 2017

Peptides and methods for inducing cell death

Inventors: Michael R. Yeaman (Redondo Beach, CA); Nannette Y. Yount (San Juan Capistrano, CA); Eric P. Brass (Palos Verdes, CA)

Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

C07K14/47 A01N47/44 C07K14/005 C12N7/00 C12N2795/10031

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,562,083
App. No.: 14/609,128
Granted: Feb 7, 2017
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease.

Claims (471)

1. An isolated peptide having 100 amino acid residues or less, comprising one or more amino acid sequence selected from the group consisting of:

(SEQ ID NO: 122)

H 2 N-QKKGKKAAATSAKKVVVS-CONH 2 ,

(SEQ ID NO: 123)

H 2 N-TKKVAVATPAKKAAVT-CONH 2 ,

(SEQ ID NO: 124)

H 2 N-KKGAAIPAKGAKNGKNAKK-CONH 2 ,

(SEQ ID NO: 125)

H 2 N-AKGKKAAKVVPVKAKNVA-CONH 2 ,

(SEQ ID NO: 126)

H 2 N-VKEAPGKRKKEMAKQKAA-CONH 2 ,

(SEQ ID NO: 127)

H 2 N-KALELTGLKVFGNEIKLEK-CONH 2 ,

(SEQ ID NO: 128)

H 2 N-KGKDSKKERDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 129)

H 2 N-IRLVSKDGKSKGIAYI-CONH 2 ,

(SEQ ID NO: 130)

H 2 N-KGQNQDYRGGKNSTWSGESKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 131)

H 2 N-KATFIKVPQNQNGKSKGYAFI-CONH 2 ,

(SEQ ID NO: 132)

H 2 N-QKKGKKA X ATSAKKV Y VS-COOH,

(SEQ ID NO: 132)

H 2 N-QKKGKKA X ATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 133)

H 2 N-QKKGKKAAATSAKKV Y VS-COOH,

(SEQ ID NO: 133)

H 2 N-QKKGKKAAATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 134)

H 2 N-QKKGKKAAATSAKKV W VS-COOH,

(SEQ ID NO: 134)

H 2 N-QKKGKKAAATSAKKV W VS-CONH 2 ,

(SEQ ID NO: 135)

H 2 N-QKKGKKA X ATSAKKV Y VS-COOH,

(SEQ ID NO: 135)

H 2 N-QKKGKKA X ATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 136)

H 2 N-QKKGKKA X ATSAKKV W VS-COOH,

(SEQ ID NO: 136)

H 2 N-QKKGKKA X ATSAKKV W VS-CONH 2 ,

(SEQ ID NO: 137)

H 2 N-KKGA X IPAKGAKNGKNAKK-COOH,

(SEQ ID NO: 137)

H 2 N-KKGA X IPAKGAKNGKNAKK-CONH 2 ,

(SEQ ID NO: 138)

H 2 N-AKGKKAAKVV X VKAKNVA-COOH,

(SEQ ID NO: 138)

H 2 N-AKGKKAAKVV X VKAKNVA-CONH 2 ,

(SEQ ID NO: 139)

H 2 N-VK B APGKRKKEMAKQKAA-COOH,

(SEQ ID NO: 139)

H 2 N-VK B APGKRKKEMAKQKAA-CONH 2 ,

(SEQ ID NO: 140)

H 2 N-VKEAPGKRKK B MAKQKAA-COOH,

(SEQ ID NO: 140)

H 2 N-VKEAPGKRKK B MAKQKAA-CONH 2 ,

(SEQ ID NO: 141)

H 2 N-VKEAPGKRKKE X AKQKAA-COOH,

(SEQ ID NO: 141)

H 2 N-VKEAPGKRKKE X AKQKAA-CONH 2 ,

(SEQ ID NO: 142)

H 2 N-VK B APGKRKK BX AKQKAA-COOH,

(SEQ ID NO: 142)

H 2 N-VK B APGKRKK BX AKQKAA-CONH 2 ,

(SEQ ID NO: 143)

H 2 N-KAL B LTGLKVFGNEIKLEK-COOH,

(SEQ ID NO: 143)

H 2 N-KAL B LTGLKVFGNEIKLEK-CONH 2 ,

(SEQ ID NO: 144)

H 2 N-KALELTGLKVFGN B IKLEK-COOH,

(SEQ ID NO: 144)

H 2 N-KALELTGLKVFGN B IKLEK-CONH 2 ,

(SEQ ID NO: 145)

H 2 N-KALELTGLKVFGNEIKL B K-COOH,

(SEQ ID NO: 145)

H 2 N-KALELTGLKVFGNEIKL B K-CONH 2 ,

(SEQ ID NO: 146)

H 2 N-KAL B LTGLKVFGN B IKL B K-COOH,

(SEQ ID NO: 146)

H 2 N-KAL B LTGLKVFGN B IKL B K-CONH 2 ,

(SEQ ID NO: 147)

H 2 N-KGK X SKKERDARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 147)

H 2 N-KGK X SKKERDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 148)

H 2 N-KGKDSKK X RDARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 148)

H 2 N-KGKDSKK X RDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 149)

H 2 N-KGKDSKKER B ARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 149)

H 2 N-KGKDSKKER B ARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 150)

H 2 N-KGK X SKK B R B ARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 150)

H 2 N-KGK X SKK B R B ARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 151)

H 2 N-IRLVSK F GKSKGIAYI-COOH,

(SEQ ID NO: 151)

H 2 N-IRLVSK F GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 152)

H 2 N-IRLVSK Y GKSKGIAYI-COOH,

(SEQ ID NO: 152)

H 2 N-IRLVSK Y GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 153)

H 2 N-IRLVSK W GKSKGIAYI-COOH,

(SEQ ID NO: 153)

H 2 N-IRLVSK W GKSKGIAYI-CONH 2 ,

(SEQ ID NO:154)

H 2 N-IRLVSK LW GKSKGIAYI-COOH,

(SEQ ID NO:154)

H 2 N-IRLVSK LW GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 155)

H 2 N-IRLVSKDGKSKG-CONH 2 ,

(SEQ ID NO: 156)

H 2 N-IRLVSK F GKSKGI-COOH,

(SEQ ID NO: 156)

H 2 N-IRLVSK F GKSKGI-CONH 2 ,

(SEQ ID NO: 157)

H 2 N-IRLVSK Y GKSKG-COOH,

(SEQ ID NO: 157)

H 2 N-IRLVSK Y GKSKG-CONH 2 ,

(SEQ ID NO: 158)

H 2 N-IRLVSK W GKSKG-COOH,

(SEQ ID NO: 158)

H 2 N-IRLVSK W GKSKG-CONH 2 ,

(SEQ ID NO: 159)

H 2 N-IRLVSK LW GKSKG-COOH,

(SEQ ID NO: 159)

H 2 N-IRLVSK LW GKSKG-CONH 2 ,

(SEQ ID NO: 160)

H 2 N-KGQNQ B YRGGKNSTWSGESKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 160)

H 2 N-KGQNQ B YRGGKNSTWSGESKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 161)

H 2 N-KGQNQDYRGGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 161)

H 2 N-KGQNQDYRGGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 162)

H 2 N-KGQNQ B YRGGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 162)

H 2 N-KGQNQ B YRGGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 163)

H 2 N-KG B NQDYRLGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 163)

H 2 N-KG B NQDYRLGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 164)

H 2 N-KG B NQDYRLGKNSTWSG B SKT-COOH,

(SEQ ID NO: 164)

H 2 N-KG B NQDYRLGKNSTWSG B SKT-CONH 2 ,

(SEQ ID NO: 165)

H 2 N-KATFIKVPQNQN X KSKGYAFI-COOH,

(SEQ ID NO: 165)

H 2 N-KATFIKVPQNQN X KSKGYAFI-CONH 2 ,

(SEQ ID NO: 166)

H 2 N-KATFIKVPQNQN L KSKGYAFI-COOH,

(SEQ ID NO: 166)

H 2 N-KATFIKVPQNQN L KSKGYAFI-CONH 2 ,

(SEQ ID NO: 167)

H 2 N-KATFIKVPQNQN Y KSKGYAFI-COOH,

(SEQ ID NO: 167)

H 2 N-KATFIKVPQNQN Y KSKGYAFI-CONH 2 ,

(SEQ ID NO: 168)

H 2 N-KATFIKVPQNQN F KSKGYAFI-COOH,

(SEQ ID NO: 168)

H 2 N-KATFIKVPQNQN F KSKGYAFI-CONH 2 ,

(SEQ ID NO: 169)

H 2 N-KATFIKVPQNQN W KSKGYAFI-COOH,

(SEQ ID NO: 169)

H 2 N-KATFIKVPQNQN W KSKGYAFI-CONH 2 ,

(SEQ ID NO: 170)

H 2 N-KATFIKVPQNQNGKSKGY-CONH 2 ,

(SEQ ID NO: 171)

H 2 N-KATFIKVPQNQN X KSKGY-COOH,

(SEQ ID NO: 171)

H 2 N-KATFIKVPQNQN X KSKGY-CONH 2 ,

(SEQ ID NO: 172)

H 2 N-KATFIKVPQNQN L KSKGY-COOH,

(SEQ ID NO: 172)

H 2 N-KATFIKVPQNQN L KSKGY-CONH 2 ,

(SEQ ID NO: 173)

H 2 N-KATFIKVPQNQN Y KSKGY-COOH,

(SEQ ID NO: 173)

H 2 N-KATFIKVPQNQN Y KSKGY-CONH 2 ,

(SEQ ID NO: 174)

H 2 N-KATFIKVPQNQN F KSKGY-COOH,

(SEQ ID NO: 174)

H 2 N-KATFIKVPQNQN F KSKGY-CONH 2 ,

(SEQ ID NO: 175)

H 2 N-KATFIKVPQNQN W KSKGY-COOH,

(SEQ ID NO: 175)

H 2 N-KATFIKVPQNQN W KSKGY-CONH 2 ,

(SEQ ID NO: 257)

H 2 N-AYLRGRYNGGAFTKTVI-CONH 2 ,

(SEQ ID NO: 258)

H 2 N-SIGSLIKRFAAKKAGVEDGRNQ-CONH 2 ,

(SEQ ID NO: 259)

H 2 N-SIGSLIKRFAAKKAGV-CONH 2 ,

(SEQ ID NO: 260)

H 2 N- O YLRGRYNGGAFTKTVI-COOH,

(SEQ ID NO: 260)

H 2 N- O YLRGRYNGGAFTKTVI-CONH 2 ,

(SEQ ID NO: 261)

H 2 N-SIGSLIKRFAAKKAGV B DGRNQ-COOH,

(SEQ ID NO: 261)

H 2 N-SIGSLIKRFAAKKAGV B DGRNQ-CONH 2 ,

(SEQ ID NO: 262)

H 2 N-SIGSLIKRFAAKKAGVE B GRNQ-COOH,

(SEQ ID NO: 262)

H 2 N-SIGSLIKRFAAKKAGVE B GRNQ-CONH 2 ,

(SEQ ID NO: 263)

H 2 N-SIGSLIKRFA X KKAGV-COOH,

(SEQ ID NO: 263)

H 2 N-SIGSLIKRFA X KKAGV-CONH 2 ,

and

(SEQ ID NO: 268)

H 2 N-SIGSLIKRFAYKKAGV-CONH 2 ,

wherein the amino acid residue represented by a bold letter denotes a substitution from the corresponding wild-type sequence and (X) is a serine, a threonine, a tryptophan, a H-bond donor residue or a H-bond acceptor residue, wherein the amino acid residue represented by (B) is a lysine, an arginine, an asparagine, a glutamine or a basic residue, wherein in the amino acid residue represented by (O) is an anthrylalanine or other non-natural amino acid and wherein said peptide induces antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity.

2. The isolated peptide of claim 1 , further comprising an activator site.

3. A method of inducing programmed cell death of a cell, comprising contacting said cell with the isolated peptide having 100 amino acid residues or less and comprising one or more amino acid sequence selected from the group consisting of:

(SEQ ID NO: 122)

H 2 N-QKKGKKAAATSAKKVVVS-COOH,

(SEQ ID NO: 122)

H 2 N-QKKGKKAAATSAKKVVVS-CONH 2 ,

(SEQ ID NO: 123)

H 2 N-TKKVAVATPAKKAAVT-COOH,

(SEQ ID NO: 123)

H 2 N-TKKVAVATPAKKAAVT-CONH 2 ,

(SEQ ID NO: 124)

H 2 N-KKGAAIPAKGAKNGKNAKK-COOH,

(SEQ ID NO: 124)

H 2 N-KKGAAIPAKGAKNGKNAKK-CONH 2 ,

(SEQ ID NO: 125)

H 2 N-AKGKKAAKVVPVKAKNVA-COOH,

(SEQ ID NO: 125)

H 2 N-AKGKKAAKVVPVKAKNVA-CONH 2 ,

(SEQ ID NO: 126)

H 2 N-VKEAPGKRKKEMAKQKAA-COOH,

(SEQ ID NO: 126)

H 2 N-VKEAPGKRKKEMAKQKAA-CONH 2 ,

(SEQ ID NO: 127)

H 2 N-KALELTGLKVFGNEIKLEK-COOH,

(SEQ ID NO: 127)

H 2 N-KALELTGLKVFGNEIKLEK-CONH 2 ,

(SEQ ID NO: 128)

H 2 N-KGKDSKKERDARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 128)

H 2 N-KGKDSKKERDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 129)

H 2 N-IRLVSKDGKSKGIAYI-COOH,

(SEQ ID NO: 129)

H 2 N-IRLVSKDGKSKGIAYI-CONH 2 ,

(SEQ ID NO: 130)

H 2 N-KGQNQDYRGGKNSTWSGESKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 130)

H 2 N-KGQNQDYRGGKNSTWSGESKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 131)

H 2 N-KATFIKVPQNQNGKSKGYAFI-COOH,

(SEQ ID NO: 131)

H 2 N-KATFIKVPQNQNGKSKGYAFI-CONH 2 ,

(SEQ ID NO: 132)

H 2 N-QKKGKKA X ATSAKKV Y VS-COOH,

(SEQ ID NO: 132)

H 2 N-QKKGKKA X ATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 133)

H 2 N-QKKGKKAAATSAKKV Y VS-COOH,

(SEQ ID NO: 133)

H 2 N-QKKGKKAAATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 134)

H 2 N-QKKGKKAAATSAKKV W VS-COOH,

(SEQ ID NO: 134)

H 2 N-QKKGKKAAATSAKKV W VS-CONH 2 ,

(SEQ ID NO: 135)

H 2 N-QKKGKKA X ATSAKKV Y VS-COOH,

(SEQ ID NO: 135)

H 2 N-QKKGKKA X ATSAKKV Y VS-CONH 2 ,

(SEQ ID NO: 136)

H 2 N-QKKGKKA X ATSAKKV W VS-COOH,

(SEQ ID NO: 136)

H 2 N-QKKGKKA X ATSAKKV W VS-CONH 2 ,

(SEQ ID NO: 137)

H 2 N-KKGA X IPAKGAKNGKNAKK-COOH,

(SEQ ID NO: 137)

H 2 N-KKGA X IPAKGAKNGKNAKK-CONH 2 ,

(SEQ ID NO: 138)

H 2 N-AKGKKAAKVV X VKAKNVA-COOH,

(SEQ ID NO: 138)

H 2 N-AKGKKAAKVV X VKAKNVA-CONH 2 ,

(SEQ ID NO: 139)

H 2 N-VK B APGKRKKEMAKQKAA-COOH,

(SEQ ID NO: 139)

H 2 N-VK B APGKRKKEMAKQKAA-CONH 2 ,

(SEQ ID NO: 140)

H 2 N-VKEAPGKRKK B MAKQKAA-COOH,

(SEQ ID NO: 140)

H 2 N-VKEAPGKRKK B MAKQKAA-CONH 2 ,

(SEQ ID NO: 141)

H 2 N-VKEAPGKRKKE X AKQKAA-COOH,

(SEQ ID NO: 141)

H 2 N-VKEAPGKRKKE X AKQKAA-CONH 2 ,

(SEQ ID NO: 142)

H 2 N-VK B APGKRKK BX AKQKAA-COOH,

(SEQ ID NO: 142)

H 2 N-VK B APGKRKK BX AKQKAA-CONH 2 ,

(SEQ ID NO: 143)

H 2 N-KAL B LTGLKVFGNEIKLEK-COOH,

(SEQ ID NO: 143)

H 2 N-KAL B LTGLKVFGNEIKLEK-CONH 2 ,

(SEQ ID NO: 144)

H 2 N-KALELTGLKVFGN B IKLEK-COOH,

(SEQ ID NO: 144)

H 2 N-KALELTGLKVFGN B IKLEK-CONH 2 ,

(SEQ ID NO: 145)

H 2 N-KALELTGLKVFGNEIKL B K-COOH,

(SEQ ID NO: 145)

H 2 N-KALELTGLKVFGNEIKL B K-CONH 2 ,

(SEQ ID NO: 146)

H 2 N-KAL B LTGLKVFGN B IKL B K-COOH,

(SEQ ID NO: 146)

H 2 N-KAL B LTGLKVFGN B IKL B K-CONH 2 ,

(SEQ ID NO: 147)

H 2 N-KGK X SKKERDARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 147)

H 2 N-KGK X SKKERDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 148)

H 2 N-KGKDSKK X RDARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 148)

H 2 N-KGKDSKK X RDARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 149)

H 2 N-KGKDSKKER B ARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 149)

H 2 N-KGKDSKKER B ARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 150)

H 2 N-KGK X SKK B R B ARTLLAKNLPYKVTQ-COOH,

(SEQ ID NO: 150)

H 2 N-KGK X SKK B R B ARTLLAKNLPYKVTQ-CONH 2 ,

(SEQ ID NO: 151)

H 2 N-IRLVSK F GKSKGIAYI-COOH,

(SEQ ID NO: 151)

H 2 N-IRLVSK F GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 152)

H 2 N-IRLVSK Y GKSKGIAYI-COOH,

(SEQ ID NO: 152)

H 2 N-IRLVSK Y GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 153)

H 2 N-IRLVSK W GKSKGIAYI-COOH,

(SEQ ID NO: 153)

H 2 N-IRLVSK W GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 154)

H 2 N-IRLVSK LW GKSKGIAYI-COOH,

(SEQ ID NO: 154)

H 2 N-IRLVSK LW GKSKGIAYI-CONH 2 ,

(SEQ ID NO: 155)

H 2 N-IRLVSKDGKSKG-COOH,

(SEQ ID NO: 155)

H 2 N-IRLVSKDGKSKG-CONH 2 ,

(SEQ ID NO: 156)

H 2 N-IRLVSK F GKSKGI-COOH,

(SEQ ID NO: 156)

H 2 N-IRLVSK F GKSKGI-CONH 2 ,

(SEQ ID NO: 157)

H 2 N-IRLVSK Y GKSKG-COOH,

(SEQ ID NO: 157)

H 2 N-IRLVSK Y GKSKG-CONH 2 ,

(SEQ ID NO: 158)

H 2 N-IRLVSK W GKSKG-COOH,

(SEQ ID NO: 158)

H 2 N-IRLVSK W GKSKG-CONH 2 ,

(SEQ ID NO: 159)

H 2 N-IRLVSK LW GKSKG-COOH,

(SEQ ID NO: 159)

H 2 N-IRLVSK LW GKSKG-CONH 2 ,

(SEQ ID NO: 160)

H 2 N-KGQNQ B YRGGKNSTWSGESKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 160)

H 2 N-KGQNQ B YRGGKNSTWSGESKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 161)

H 2 N-KGQNQDYRGGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 161)

H 2 N-KGQNQDYRGGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 162)

H 2 N-KGQNQ B YRGGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 162)

H 2 N-KGQNQ B YRGGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 163)

H 2 N-KG B NQDYRLGKNSTWSG B SKTLVLSNLSYSAT-COOH,

(SEQ ID NO: 163)

H 2 N-KG B NQDYRLGKNSTWSG B SKTLVLSNLSYSAT-CONH 2 ,

(SEQ ID NO: 164)

H 2 N-KG B NQDYRLGKNSTWSG B SKT-COOH,

(SEQ ID NO: 164)

H 2 N-KG B NQDYRLGKNSTWSG B SKT-CONH 2 ,

(SEQ ID NO: 165)

H 2 N-KATFIKVPQNQN X KSKGYAFI-COOH,

(SEQ ID NO: 165)

H 2 N-KATFIKVPQNQN X KSKGYAFI-CONH 2 ,

(SEQ ID NO: 166)

H 2 N-KATFIKVPQNQN L KSKGYAFI-COOH,

(SEQ ID NO: 166)

H 2 N-KATFIKVPQNQN L KSKGYAFI-CONH 2 ,

(SEQ ID NO: 167)

H 2 N-KATFIKVPQNQN Y KSKGYAFI-COOH,

(SEQ ID NO: 167)

H 2 N-KATFIKVPQNQN Y KSKGYAFI-CONH 2 ,

(SEQ ID NO: 168)

H 2 N-KATFIKVPQNQN F KSKGYAFI-COOH,

(SEQ ID NO: 168)

H 2 N-KATFIKVPQNQN F KSKGYAFI-CONH 2 ,

(SEQ ID NO: 169)

H 2 N-KATFIKVPQNQN W KSKGYAFI-COOH,

(SEQ ID NO: 169)

H 2 N-KATFIKVPQNQN W KSKGYAFI-CONH 2 ,

(SEQ ID NO: 170)

H 2 N-KATFIKVPQNQNGKSKGY-CONH 2 ,

(SEQ ID NO: 171)

H 2 N-KATFIKVPQNQN X KSKGY-COOH,

(SEQ ID NO: 171)

H 2 N-KATFIKVPQNQN X KSKGY-CONH 2 ,

(SEQ ID NO: 172)

H 2 N-KATFIKVPQNQN L KSKGY-COOH,

(SEQ ID NO: 172)

H 2 N-KATFIKVPQNQN L KSKGY-CONH 2 ,

(SEQ ID NO: 173)

H 2 N-KATFIKVPQNQN Y KSKGY-COOH,

(SEQ ID NO: 173)

H 2 N-KATFIKVPQNQN Y KSKGY-CONH 2 ,

(SEQ ID NO: 174)

H 2 N-KATFIKVPQNQN F KSKGY-COOH,

(SEQ ID NO: 174)

H 2 N-KATFIKVPQNQN F KSKGY-CONH 2 ,

(SEQ ID NO: 175)

H 2 N-KATFIKVPQNQN W KSKGY-COOH,

(SEQ ID NO: 175)

H 2 N-KATFIKVPQNQN W KSKGY-CONH 2 ,

(SEQ ID NO: 257)

H 2 N-AYLRGRYNGGAFTKTVI-CONH 2 ,

(SEQ ID NO: 258)

H 2 N-SIGSLIKRFAAKKAGVEDGRNQ-CONH 2 ,

(SEQ ID NO: 259)

H 2 N-SIGSLIKRFAAKKAGV-CONH 2 ,

(SEQ ID NO: 260)

H 2 N- O YLRGRYNGGAFTKTVI-COOH,

(SEQ ID NO: 260)

H 2 N- O YLRGRYNGGAFTKTVI-CONH 2 ,

(SEQ ID NO: 261)

H 2 N-SIGSLIKRFAAKKAGV B DGRNQ-COOH,

(SEQ ID NO: 261)

H 2 N-SIGSLIKRFAAKKAGV B DGRNQ-CONH 2 ,

(SEQ ID NO: 262)

H 2 N-SIGSLIKRFAAKKAGVE B GRNQ-COOH,

(SEQ ID NO: 262)

H 2 N-SIGSLIKRFAAKKAGVE B GRNQ-CONH 2 ,

(SEQ ID NO: 263)

H 2 N-SIGSLIKRFA X KKAGV-COOH,

(SEQ ID NO: 263)

H 2 N-SIGSLIKRFA X KKAGV-CONH 2 ,

and

(SEQ ID NO: 268)

H 2 N-SIGSLIKRFAYKKAGV-CONH 2 ,

4. The method of claim 3 , wherein said cell is a microorganism.

5. The method of claim 4 , wherein said microorganism is a pathogenic microorganism.

6. The method of claim 5 , wherein said pathogenic microorganism is selected from the group consisting of Staphylococcus aureus, Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa, Bacillus subtilis, Acinotobacter baumannii, Acinotobacter calcoaceticus, Acinotobacter haemolyticus, Pseudomonas aeruginosa and Candida albicans.

7. The method of claim 3 , wherein said cell is a tumor cell.

8. The method of claim 7 , wherein said tumor cell is a malignant tumor cell.

9. The method of claim 3 , wherein said cell is an immune regulatory cell or an immune effector cell.

10. The isolated peptide of claim 1 , wherein the peptide has 75 amino acid residues or less.

11. The isolated peptide of claim 1 , wherein the peptide has 50 amino acid residues or less.

12. The isolated peptide of claim 1 , wherein the peptide consists of SEQ ID NO: 152.

13. The isolated peptide of claim 1 , wherein the peptide consists of SEQ ID NO: 268.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2016

From: YEAMAN, MICHAEL R.; YOUNT, NANNETTE Y.; BRASS, ERIC P.

To: LOS ANGELES BIOIMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER

Reel/Frame 040691/0634 →

Continuity (4)

Continuation 13875066 · May 1, 2013

Continuation 12932298 · Feb 22, 2011

Provisional Application 61338747 · Feb 22, 2010

Related Publication 20150232521A1 · Aug 20, 2015